ReviewTherapeutics and clinical risk management2022

Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives.

Elena Niculet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.